Search

Your search keyword '"Mazzatenta C."' showing total 118 results
Start Over Author "Mazzatenta C." Publication Year Range Last 10 years
118 results on '"Mazzatenta C."'

1. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

Author

Russo F, Galluzzo M, Stingeni L, Persechino S, Zichichi L, Conti A, Giofrè C, Dini V, Vispi M, Atzori L, Cattaneo A, Parodi A, Bardazzi F, Stinco G, Dapavo P, Girolomoni G, Musumeci ML, Papini M, Venturini M, Dastoli S, Di Nuzzo S, Fargnoli MC, Pagnanelli G, Bernardini N, Gambini DM, Malagoli P, Mazzatenta C, Peris K, Zalaudek I, Fabbrocini G, Loconsole F, Vassallo C, Pietroleonardo L, Prignano F, Franchi C, Offidani AM, Bonifati C, Di Lernia V, Gigante G, Bartezaghi MS, Franchi M, Ursoleo P, and Aloisi E

Subjects
psoriasis, secukinumab, real-world evidence, drug survival, supreme, Dermatology, RL1-803
Abstract

Filomena Russo,1 Marco Galluzzo,2,3 Luca Stingeni,4 Severino Persechino,5 Leonardo Zichichi,6 Andrea Conti,7 Claudia Giofrè,8 Valentina Dini,9 Martina Vispi,10 Laura Atzori,11 Angelo Cattaneo,12 Aurora Parodi,13 Federico Bardazzi,14 Giuseppe Stinco,15 Paolo Dapavo,16 Giampiero Girolomoni,17 Maria Letizia Musumeci,18 Manuela Papini,19 Marina Venturini,20 Stefano Dastoli,21 Sergio Di Nuzzo,22 Maria Concetta Fargnoli,23 Gianluca Pagnanelli,24 Nicoletta Bernardini,25 Daniele Mario Gambini,26 Piergiorgio Malagoli,27 Carlo Mazzatenta,28 Ketty Peris,29 Iris Zalaudek,30 Gabriella Fabbrocini31 ,† Francesco Loconsole,32 Camilla Vassallo,33 Lucia Pietroleonardo,34 Francesca Prignano,35 Chiara Franchi,36 Anna Maria Offidani,37 Claudio Bonifati,38 Vito Di Lernia,39 Giovanni Gigante,40 Marta Silvia Bartezaghi,40 Matteo Franchi,41,42 Paola Ursoleo,40 Elisabetta Aloisi40 1Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria Alle Scotte Hospital, Siena, Italy; 2Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy; 3Dermatology Unit, Fondazione Policlinico “Tor Vergata”, Rome, Italy; 4Section of Dermatology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 5Dermatology Unit, NESMOS Department, Faculty of Medicine & Psychology, Sapienza University of Rome, Sant’Andrea University Hospital, Rome, Italy; 6Unit of Dermatology, San Antonio Abate Hospital, Trapani, Italy; 7Section of Dermatology, Department of Specialized Medicine, University of Modena and Reggio Emilia, Modena, Italy; 8U.O.C. Dermatologia, A.O. Papardo, Messina, Italy; 9Section of Dermatology, Department of Medicine and Oncology, University of Pisa, Pisa, Italy; 10Dermatology Unit, Misericordia Hospital, Grosseto, Italy; 11Dermatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 12Dermatology Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy; 13Section of Dermatology, DiSSal University of Genoa, Ospedale-Policlinico San Martino IRCCS, Genova, Italy; 14Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; 15Section of Dermatology, Department of Medicine, University of Udine, Udine, Italy; 16Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy; 17Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy; 18Section of Dermatology, Department of Medical and Surgical Specialties, University of Catania, Catania, Italy; 19Dermatology Clinic of Terni, University of Perugia, Perugia, Italy; 20Section of Dermatology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 21Department of Health Sciences, Magna Graecia University, Catanzaro, Italy; 22Department of Medicine and Surgery, University of Parma, Parma, Italy; 23Section of Dermatology, Department of Biotechnological and Applied Clinical Science, University of L’Aquila, L’Aquila, Italy; 24Department of Dermatology, Istituto Dermopatico dell’Immacolata - IRCCS, Roma, Italy; 25Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Dermatology Unit, “Daniele Innocenzi”, Asl Latina, Italy; 26Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy; 27Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy; 28Dermatology Unit, Lucca Azienda USL Toscana Nord Ovest, Pisa, Italy; 29Department of Translational Medicine and Surgery, IRCCS A. Gemelli University Polyclinic Foundation, Sacred Heart Catholic University, Rome, Italy; 30Department of Dermatology, University of Trieste, Trieste, Italy; 31Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 32Department of Dermatology, University of Bari, Bari, Italy; 33Institute of Dermatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy; 34Dermatology Unit, Vito Fazzi Hospital, Lecce, Italy; 35Dermatology Clinic, Department of Health Sciences, University of Florence, Florence, Italy; 36Dermatology Unit, IRCCS IO Galeazzi, Milan, Italy; 37Dermatological Clinic, Polytechnic University of the Marche Region, Ancona, Italy; 38Department of Dermatology, Istituto Dermatologico San Gallicano - IRCCS, Roma, Italy; 39Dermatology Unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy; 40Novartis Farma SpA, Origgio, Italy; 41National Centre for Healthcare Research and Pharmacoepidemiology, Milan, Italy; 42Laboratory of Healthcare Research and Pharmacoepidemiology, Department of Statistics and Quantitative Methods, University of Milano Bicocca, Milan, Italy†Gabriella Fabbrocini passed away on 3 March 2023Correspondence: Filomena Russo, Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, S. Maria Alle Scotte Hospital, Siena, Italy, Email file.russo@libero.itPurpose: SUPREME, a phase IIIb study conducted in Italy, demonstrated safety and high efficacy of secukinumab for up to 72 weeks in patients with moderate-to-severe plaque-type psoriasis. SUPREME 2.0 study aimed to provide real-world data on the long-term drug survival and effectiveness of secukinumab beyond 72 weeks.Patients and Methods: SUPREME 2.0 is a retrospective observational chart review study conducted in patients previously enrolled in SUPREME study. After the end of the SUPREME study, eligible patients continued treatment as per clinical practice, and their effectiveness and drug survival data were retrieved from medical charts.Results: Of the 415 patients enrolled in the SUPREME study, 297 were included in SUPREME 2.0; of which, 210 (70.7%) continued secukinumab treatment throughout the 42-month observation period. Patients in the biologic-naïve cohort had higher drug survival than those in the biologic-experienced cohort (74.9% vs 61.7%), while HLA-Cw6–positive and HLA-Cw6–negative patients showed similar drug survival (69.3% and 71.9%). After 42 months, Psoriasis Area and Severity Index (PASI) 90 was achieved by 79.6% of patients overall; with a similar proportion of biologic-naïve and biologic-experienced patients achieving PASI90 (79.8% and 79.1%). The mean absolute PASI score reduced from 21.94 to 1.38 in the overall population, 21.90 to 1.24 in biologic-naïve and 22.03 to 1.77 in biologic-experienced patients after 42 months. The decrease in the absolute PASI score was comparable between HLA-Cw6–positive and HLA–Cw6-negative patients. The baseline Dermatology Life Quality Index scores also decreased in the overall patients (10.5 to 2.32) and across all study sub-groups after 42 months. Safety was consistent with the known profile of secukinumab, with no new findings.Conclusion: In this real-world cohort study, secukinumab showed consistently high long-term drug survival and effectiveness with a favourable safety profile.Keywords: psoriasis, secukinumab, real-world evidence, drug survival, SUPREME

Published
2023

2. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

Author

Russo, F, Galluzzo, M, Stingeni, L, Persechino, S, Zichichi, L, Conti, A, Giofrè, C, Dini, V, Vispi, M, Atzori, L, Cattaneo, A, Parodi, A, Bardazzi, F, Stinco, G, Dapavo, P, Girolomoni, G, Musumeci, M, Papini, M, Venturini, M, Dastoli, S, Di Nuzzo, S, Fargnoli, M, Pagnanelli, G, Bernardini, N, Gambini, D, Malagoli, P, Mazzatenta, C, Peris, K, Zalaudek, I, Fabbrocini, G, Loconsole, F, Vassallo, C, Pietroleonardo, L, Prignano, F, Franchi, C, Offidani, A, Bonifati, C, Di Lernia, V, Gigante, G, Bartezaghi, M, Franchi, M, Ursoleo, P, Aloisi, E, Russo, Filomena, Galluzzo, Marco, Stingeni, Luca, Persechino, Severino, Zichichi, Leonardo, Conti, Andrea, Giofrè, Claudia, Dini, Valentina, Vispi, Martina, Atzori, Laura, Cattaneo, Angelo, Parodi, Aurora, Bardazzi, Federico, Stinco, Giuseppe, Dapavo, Paolo, Girolomoni, Giampiero, Musumeci, Maria Letizia, Papini, Manuela, Venturini, Marina, Dastoli, Stefano, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Pagnanelli, Gianluca, Bernardini, Nicoletta, Gambini, Daniele, Malagoli, Piergiorgio, Mazzatenta, Carlo, Peris, Ketty, Zalaudek, Iris, Fabbrocini, Gabriella, Loconsole, Francesco, Vassallo, Camilla, Pietroleonardo, Lucia, Prignano, Francesca, Franchi, Chiara, Offidani, Anna Maria, Bonifati, Claudio, Di Lernia, Vito, Gigante, Giovanni, Bartezaghi, Marta, Franchi, Matteo, Ursoleo, Paola, Aloisi, Elisabetta, Russo, F, Galluzzo, M, Stingeni, L, Persechino, S, Zichichi, L, Conti, A, Giofrè, C, Dini, V, Vispi, M, Atzori, L, Cattaneo, A, Parodi, A, Bardazzi, F, Stinco, G, Dapavo, P, Girolomoni, G, Musumeci, M, Papini, M, Venturini, M, Dastoli, S, Di Nuzzo, S, Fargnoli, M, Pagnanelli, G, Bernardini, N, Gambini, D, Malagoli, P, Mazzatenta, C, Peris, K, Zalaudek, I, Fabbrocini, G, Loconsole, F, Vassallo, C, Pietroleonardo, L, Prignano, F, Franchi, C, Offidani, A, Bonifati, C, Di Lernia, V, Gigante, G, Bartezaghi, M, Franchi, M, Ursoleo, P, Aloisi, E, Russo, Filomena, Galluzzo, Marco, Stingeni, Luca, Persechino, Severino, Zichichi, Leonardo, Conti, Andrea, Giofrè, Claudia, Dini, Valentina, Vispi, Martina, Atzori, Laura, Cattaneo, Angelo, Parodi, Aurora, Bardazzi, Federico, Stinco, Giuseppe, Dapavo, Paolo, Girolomoni, Giampiero, Musumeci, Maria Letizia, Papini, Manuela, Venturini, Marina, Dastoli, Stefano, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Pagnanelli, Gianluca, Bernardini, Nicoletta, Gambini, Daniele, Malagoli, Piergiorgio, Mazzatenta, Carlo, Peris, Ketty, Zalaudek, Iris, Fabbrocini, Gabriella, Loconsole, Francesco, Vassallo, Camilla, Pietroleonardo, Lucia, Prignano, Francesca, Franchi, Chiara, Offidani, Anna Maria, Bonifati, Claudio, Di Lernia, Vito, Gigante, Giovanni, Bartezaghi, Marta, Franchi, Matteo, Ursoleo, Paola, and Aloisi, Elisabetta

Abstract

Purpose: SUPREME, a phase IIIb study conducted in Italy, demonstrated safety and high efficacy of secukinumab for up to 72 weeks in patients with moderate-to-severe plaque-type psoriasis. SUPREME 2.0 study aimed to provide real-world data on the long-term drug survival and effectiveness of secukinumab beyond 72 weeks. Patients and Methods: SUPREME 2.0 is a retrospective observational chart review study conducted in patients previously enrolled in SUPREME study. After the end of the SUPREME study, eligible patients continued treatment as per clinical practice, and their effectiveness and drug survival data were retrieved from medical charts. Results: Of the 415 patients enrolled in the SUPREME study, 297 were included in SUPREME 2.0; of which, 210 (70.7%) continued secukinumab treatment throughout the 42-month observation period. Patients in the biologic-naïve cohort had higher drug survival than those in the biologic-experienced cohort (74.9% vs 61.7%), while HLA-Cw6–positive and HLA-Cw6–negative patients showed similar drug survival (69.3% and 71.9%). After 42 months, Psoriasis Area and Severity Index (PASI) 90 was achieved by 79.6% of patients overall; with a similar proportion of biologic-naïve and biologic-experienced patients achieving PASI90 (79.8% and 79.1%). The mean absolute PASI score reduced from 21.94 to 1.38 in the overall population, 21.90 to 1.24 in biologic-naïve and 22.03 to 1.77 in biologic-experienced patients after 42 months. The decrease in the absolute PASI score was comparable between HLA-Cw6–positive and HLA–Cw6-negative patients. The baseline Dermatology Life Quality Index scores also decreased in the overall patients (10.5 to 2.32) and across all study sub-groups after 42 months. Safety was consistent with the known profile of secukinumab, with no new findings. Conclusion: In this real-world cohort study, secukinumab showed consistently high long-term drug survival and effectiveness with a favourable safety profile.

Published
2023

4. Update on the Management of Pediatric Psoriasis: An Italian Consensus

Author

Peris, Ketty, Fortina, A. B., Bianchi, L., Fabbrocini, G., Gisondi, P., Balato, A., Bardazzi, F., Bernardini, N., Bonamonte, D., Bongiorno, M. R., Buligan, C., Cusano, F., Del Giudice, M. B. D. F., Hachem, M. E., Fargnoli, Maria Concetta, Gualdi, G., Guarneri, C., Hansel, K., Malara, G., Mazzatenta, C., Micali, G., Narcisi, A., Neri, I., Oranges, T., Panzone, M., Parodi, A., Restano, L., Simonetti, O., Venturini, M., Di Lernia, V., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Peris, Ketty, Fortina, A. B., Bianchi, L., Fabbrocini, G., Gisondi, P., Balato, A., Bardazzi, F., Bernardini, N., Bonamonte, D., Bongiorno, M. R., Buligan, C., Cusano, F., Del Giudice, M. B. D. F., Hachem, M. E., Fargnoli, Maria Concetta, Gualdi, G., Guarneri, C., Hansel, K., Malara, G., Mazzatenta, C., Micali, G., Narcisi, A., Neri, I., Oranges, T., Panzone, M., Parodi, A., Restano, L., Simonetti, O., Venturini, M., Di Lernia, V., Peris K. (ORCID:0000-0002-5237-0463), and Fargnoli M. C.

Abstract

Introduction: Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed. Methods: In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced. Results: There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy. Conclusions: Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis

Published
2022

8. Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis. The LION real-life multicenter prospective observational cohort study

Author

Campanati, A., Atzori, L., Potenza, C., Damiani, G., Bianchi, L., Corazza, M., Tiberio, R., Prignano, F., Argenziano, G., Fargnoli, M. C., Stingeni, L., Mazzotta, A., De Pita, O., Mazzatenta, C., Feliciani, C., Donini, M., Offidani, A., Peris, K., Rongioletti, F., Pigatto, P., Cruciani, G., De Simone, C., Caldarola, G., Grimaldi, M., Anedda, J., Bernardini, N., Marchesiello, A., Franchi, C., Dattola, A., Botti, E., Zedde, P., Cammarata, E., Radi, G., Rosi, E., De Rosa, A., Esposito, M., Marietti, R., Lupi, F., Grazzini, M., Domenico, D. M., Brusasco, M., Gai, F., Campanati, A., Atzori, L., Potenza, C., Damiani, G., Bianchi, L., Corazza, M., Tiberio, R., Prignano, F., Argenziano, G., Fargnoli, M. C., Stingeni, L., Mazzotta, A., De Pita, O., Mazzatenta, C., Feliciani, C., Donini, M., Offidani, A., Peris, K., Rongioletti, F., and on behalf of the LION study group—Italian Participating, Centers

Subjects
Adult, Male, medicine.medical_specialty, Dermatologic Agent, psoriasis, therapy-topical, Betamethasone dipropionate, Dermatology, Betamethasone, NO, chemistry.chemical_compound, Patient satisfaction, Calcitriol, Psoriasis, Internal medicine, Drug Combination, medicine, Humans, Prospective Studies, Prospective cohort study, Calcipotriol, psoriasi, therapy-topical, business.industry, psoriasis, General Medicine, Middle Aged, medicine.disease, Prospective Studie, Drug Combinations, Treatment Outcome, chemistry, Patient Satisfaction, Cohort, Observational study, Dermatologic Agents, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business, Cohort study, medicine.drug, Human
Abstract

Topical treatment is the mainstay for mild or moderate psoriasis, but patients are generally little satisfied. Calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam has shown to improve signs and symptoms in plaque psoriasis patients. This study assessed patient's satisfaction with Cal/BD foam in a real-life Italian dermatological clinical practice. A multicenter, 4-week observational prospective cohort study enrolled, in 17 Italian dermatology clinics, adult patients with plaque psoriasis on the body and/or scalp. Treatment satisfaction was assessed by 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), preference over previous treatments by Patient Preference Questionnaire (PPQ), and change in disease state by Psoriasis Area Severity Index (PASI). Overall 256 patients were eligible, with a mean (SD) age of 55.6 (15.4) years, 59.4% were males. Psoriasis severity was mild in 52.0% of patients, moderate in 43.3%, and severe in 4.7%. Scalp involvement was present in 36.7% of patients. Previous antipsoriatic treatments had been received by 80.5% of patients. TSQM-9 median (25th-75th percentile) scores were 83.3 (66.7-88.9) for effectiveness, 77.8 (66.7-88.9) for convenience, and 78.6 (64.3-92.9) for global satisfaction. Mean (SD) PASI value decreased from 7.3 (4.8) to 2.1 (2.7) after 4 weeks. More than 90% of patients previously treated for psoriasis evaluated the Cal/BD foam more effective, easier to use and better tolerated compared to previous topical treatments at PPQ. This observational study provides real-life evidence of a high level of satisfaction with effectiveness and convenience of the Cal/BD foam in a cohort of plaque psoriasis patients, with an objective improvement in PASI.

Published
2021

11. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry*

Author

Gisondi, P., Cazzaniga, S., Chimenti, S., Maccarone, M., Picardo, M., Girolomoni, G., Naldi, L., Griseta, V., Miracapillo, A., Azzini, M., Mocci, L., Michelini, M., Offidani, A., Bernardini, L., Campanati, A., Ricotti, G., Giacchetti, A., Norat, M., Gualco, F., Castelli, A., Cuccia, A., Diana, A., Roncarolo, G., Belli, M. A., Baldassarre, M. A., Santoro, G., Vena, G. A., Lo Console, F., Filotico, R., Mastrandrea, V., Brunetti, B., Musumeci, F., Carrabba, E., Dal Mas, P., Annicchiarico, F., Benvegnù, B., Spaziani, G., Cusano, F., Iannazzone, Saletta S., Galluccio, A., Pezza, M., Marchesi, L., Imberti, G., Reseghetti, A., Barbera, C., Reggiani, M., Lanzoni, A., Patrizi, A., Bardazzi, F., Antonucci, A., De Tommaso, S., Balestri, R., Wallnofer, W., Ingannamorte, F., Calzavara-Pinton, P., Iannazzi, S., Zane, C., Capezzera, R., Bassisi, S., Rossi, M. T., Altamura, V., Vigl, W., Nobile, C., Aste, N., Murgia, S., Mugheddu, C., Scuderi, G., Baglieri, F., Di Dio, C., Grilli, Cilioni E., Mastronardi, C., Agnusdei, C. P., Antrilli, A., Aulisa, L., Raimondo, U., di Luzio, Scotto G., Battarra, V. C., Farro, P., Plaitano, R., Micali, G., Musumeci, M. L., Massimino, D., Li Calzi, M., La Greca, S., Pettinato, M., Sapienza, G., Valenti, G., De Giacomo, P. F., dʼAmico, D., Arcangeli, F., Brunelli, D., Ghetti, E., Tulli, A., Assi, G., Laria, G., Prestinari, F., Spadafora, S., Coppola, M., Caresana, G., Pezzarossa, E., Domaneschi, E., Felisi, C., Donato, L., Bertero, M., Musso, L., Pa lazzini, S., Bruscino, P., Agozzino, U. C., Ottaviani, M., Simoncini, C., Virgili, A., Osti, F., Fabbri, P., Volpi, W., Caproni, M., Lotti, T., Prignano, F., Buggiani, G., Troiano, M., Fenizi, G., Altobella, A., Amoruso, A., Condello, M., Goffredo, A., Righini, M. G., Alessandrini, F., Satolli, F., Zampetti, M., Bertani, E., Fossati, S., Parodi, A., Burlando, M., Fiorucci, C., Nigro, A., Ghigliotti, G., Massone, L., Moise, G. M., Serrai, M., Cannata, G., Campagnoli, A. M., Daly, M., Leporati, C., Peila, R., Filosa, G., Bugatti, L., Nicolini, M., Nazzari, G., Cestari, R., Anastasio, F., Larussa, F. M., Pollice, N., De Francesco, F., Mazzocchetti, G., Peris, K., Fargnoli, M. C., Di Cesare, A., De Angelis, L., Flati, G., Biamonte, A. S., Quarta, G., Congedo, M., Carcaterra, A., Strippoli, D., Fideli, D., Marsili, F., Celli, M., Ceccarini, M., Bachini, L., DʼOria, M., Schirripa, V., De Filippi, C., Martini, P., Lapucci, E., Mazzatenta, C., Ghilardi, A., Simonacci, M., Bettacchi, A., Gasco, R., Zanca, A., Battistini, S., Dattola, S., Vernaci, R., Postorino, F., Zampieri, P. F., Padovan, C., González Intchaurraga, M. A., Ladurner, J., Guarneri, B., Cannavò, S., Manfrè, C., Borgia, F., Guerra, Puglisi A., Sedona, P., Cattaneo, A., Carrera, C., Fracchiolla, C., Mozzanica, N., Prezzemolo, L., Menni, S., Lodi, A., Martino, P., Monti, M., Mancini, L., Sacrini, F., Altomare, G. F., Taglioni, M., Lovati, C., Mercuri, S. R., Schiesari, G., Giannetti, A., Conti, A., Lasagni, C., Greco, M., Ronsini, G., Schianchi, S., Fiorentini, C., Niglietta, S., Maglietta, R., Padalino, C., Crippa, D., Pini, M., Rossi, E., Tosi, D., Armas, M., Ruocco, V., Ayala, F., Balato, N., Gaudiello, F., Cimmino, G. F., Monfrecola, G., Gallo, L., Argenziano, G., Fulgione, E., Berruti, G., Mozzillo, R., Ceparano, S., De Michele, I., Giorgiano, D., Leigheb, G., Deledda, S., Peserico, A., Alaibac, M., Piaserico, S., Schiesari, L., Dan, G., Mattei, I., Oro, E., Aricò, M., Bongiorno, M. R., Angileri, R., Amato, S., Todaro, F., Milioto, M., Bellastro, R., Di Nuzzo, S., De Panfilis, G., Zanni, M., Borroni, G., Cananzi, R., Brazzelli, V., Lisi, P., Stingeni, L., Hansel, K., Pierfelice, V., Donelli, S., Rastelli, D., Gasperini, M., Barachini, P., Cecchi, R., Bartoli, L., Pavesi, M., De Paola, S., Corradin, M. T., Ricciuti, F., Piccirillo, A., Viola, L., Tataranni, M., Mautone, M. G., Lo Scocco, G., Niccoli, M. C., Brunasso Vernetti, A. M.G., Gaddoni, G., Resta, F., Casadio, M. C., Arcidiaco, M. C., Luvarà, M. C., Albertini, G., Di Lernia, V., Guareschi, E., Catrani, S., Morri, M., Amerio, P., De Simone, C., DʼAgostino, M., Agostino, I., Calvieri, S., Cantoresi, F., Richetta, A., Sorgi, P., Carnevale, C., Nicolucci, F., Berardesca, E., Ardigò, M., De Felice, C., Gubinelli, E., Talamonti, M., Camplone, G., Cruciani, G., Riccardi, F., Barbati, R., Pagani, W., Malagoli, P. G., Pellicano, R., Donadio, D., Di Vito, C., Cottoni, F., Montesu, M. A., Pirodda, C., Addis, G., Marongiu, P., Farris, A., Cacciapuoti, M., Verrini, A., Desirello, G., Gnone, M., Fimiani, M., Pellegrino, M., Castelli, G., Zappalà, L., Sesana, G., Ingordo, V., Vozza, E., Di Giuseppe, D., Fasciocco, D., Nespoli, P., Papini, M., Cicoletti, M., Bernengo, M. G., Ortoncelli, M., Bonvicino, A., Capella, G., Doveil, G. C., Forte, M., Peroni, A., Salomone, B., Savoia, P., Pippione, M., Zichichi, L., Frazzitta, M., De Luca, G., Tasin, L., Simonetto, D., Ros, S., Trevisan, G., Patamia, M., Miertusova, S., Patrone, P., Frattasio, A., Piccirillo, F., La Spina, S., Di Gaetano, L., Marzocchi, V., Motolese, A., Venturi, C., Gai, F., Pasquinucci, S., Bellazzi, R. M., Silvestri, T., Fornasa, Veller C., and Trevisan, G. P.

Published
2015
Full Text
View/download PDF

19. Pruritus characteristics in a large Italian cohort of psoriatic patients

Author

Damiani, G., Cazzaniga, S., Conic, R. R. Z., Naldi, L., Griseta, V., Miracapillo, A., Azzini, M., Mocci, L., Michelini, M., Offidani, A., Bernardini, L., Campanati, A., Ricotti, G., Giacchetti, A., Norat, M., Gualco, F., Castelli, A., Cuccia, A., Diana, A., Roncarolo, G., Belli, M. A., Baldassarre, M. A., Santoro, G., Vena, G. A., Lo Console, F., Filotico, R., Mastrandrea, V., Brunetti, B., Musumeci, F., Carrabba, E., Dal Mas, P., Annicchiarico, F., Benvegnu, B., Spaziani, G., Cusano, F., Saletta Iannazzone, S., Galluccio, A., Pezza, M., Marchesi, L., Imberti, G., Reseghetti, A., Barbera, C., Reggiani, M., Lanzoni, A., Patrizi, A., Bardazzi, F., Antonucci, A., De Tommaso, S., Wallnofer, W., Ingannamorte, F., Calzavara-Pinton, P., Iannazzi, S., Zane, C., Capezzera, R., Bassisi, S., Rossi, M. T., Altamura, V., Vigl, W., Nobile, C., Aste, N., Murgia, S., Mugheddu, C., Scuderi, G., Baglieri, F., Di Dio, C., Cilioni Grilli, E., Mastronardi, C., Agnusdei, C. P., Antrilli, A., Aulisa, L., Raimondo, U., Scotto di Luzio, G., Battarra, V. C., Farro, P., Plaitano, R., Micali, G., Musumeci, M. L., Massimino, D., Li Calzi, M., La Greca, S., Pettinato, M., Sapienza, G., Valenti, G., De Giacomo, P. F., Amico, Arcangeli, F., Brunelli, D., Ghetti, E., Tulli, A., Assi, G., Amerio, P., Laria, G., Prestinari, F., Spadafora, S., Coppola, M., Caresana, G., Pezzarossa, E., Felisi, C., Donato, L., Bertero, M., Musso, L., Pa lazzini, S., Bruscino, P., Agozzino, U. C., Ottaviani, M., Simoncini, C., Virgili, A., Osti, F., Fabbri, P., Volpi, W., Caproni, M., Lotti, T., Prignano, F., Buggiani, G., Troiano, M., Fenizi, G., Altobella, A., Amoruso, A., Condello, M., Goffredo, A., Righini, M. G., Alessandrini, F., Satolli, F., Zampetti, M., Bertani, E., Fossati, S., Parodi, A., Burlando, M., Fiorucci, C., Nigro, A., Ghigliotti, G., Massone, L., Moise, G. M., Serrai, M., Cannata, G., Campagnoli, A. M., Daly, M., Leporati, C., Peila, R., Filosa, G., Bugatti, L., Nicolini, M., Nazzari, G., Cestari, R., Anastasio, F., Larussa, F. M., Pollice, N., De Francesco, F., Mazzocchetti, G., Peris, K., Fargnoli, M. C., Di Cesare, A., De Angelis, L., Flati, G., Biamonte, A. S., Quarta, G., Congedo, M., Carcaterra, A., Strippoli, D., Fideli, D., Marsili, F., Celli, M., Ceccarini, M., Bachini, L., D'Oria, M., Schirripa, V., De Filippi, C., Martini, P., Lapucci, E., Mazzatenta, C., Ghilardi, A., Simonacci, M., Bettacchi, A., Gasco, R., Zanca, A., Battistini, S., Dattola, S., Vernaci, R., Postorino, F., Zampieri, P. F., Padovan, C., Gonzalez Intchaurraga, M. A., Ladurner, J., Guarneri, B., Cannavo, S., Manfre, C., Borgia, F., Puglisi Guerra, A., Cattaneo, A., Carrera, C., Fracchiolla, C., Mozzanica, N., Prezzemolo, L., Menni, S., Lodi, A., Martino, P., Monti, M., Mancini, L., Sacrini, F., Altomare, G. F., Taglioni, M., Lovati, C., Mercuri, S. R., Schiesari, G., Giannetti, A., Conti, A., Lasagni, C., Greco, M., Ronsini, G., Schianchi, S., Fiorentini, C., Niglietta, S., Maglietta, R., Padalino, C., Crippa, D., Pini, M., Rossi, E., Tosi, D., Armas, M., Ruocco, V., Ayala, F., Balato, N., Gaudiello, F., Cimmino, G. F., Monfrecola, G., Gallo, L., Argenziano, G., Fulgione, E., Berruti, G., Ceparano, S., De Michele, I., Giorgiano, D., Leigheb, G., Deledda, S., Peserico, A., Alaibac, M., Piaserico, S., Schiesari, L., Dan, G., Mattei, I., Oro, E., Arico, M., Bongiorno, M. R., Angileri, R., Amato, S., Todaro, F., Milioto, M., Bellastro, R., Di Nuzzo, S., De Panfilis, G., Zanni, M., Borroni, G., Cananzi, R., Brazzelli, V., Lisi, P., Stingeni, L., Hansel, K., Pierfelice, V., Donelli, S., Rastelli, D., Gasperini, M., Barachini, P., Cecchi, R., Bartoli, L., Pavesi, M., De Paola, S., Corradin, M. T., Ricciuti, F., Piccirillo, A., Viola, L., Tataranni, M., Mautone, M. G., Lo Scocco, G., Niccoli, M. C., Brunasso Vernetti, A. M. G., Gaddoni, G., Resta, F., Casadio, M. C., Arcidiaco, M. C., Luvara, M. C., Albertini, G., Di Lernia, V., Guareschi, E., Catrani, S., Morri, M., De Simone, C., D'Agostino, M., Agostino, I., Calvieri, S., Cantoresi, F., Richetta, A., Sorgi, P., Carnevale, C., Nicolucci, F., Berardesca, E., Ardigo, M., De Felice, C., Gubinelli, E., Talamonti, M., Camplone, G., Cruciani, G., Riccardi, F., Barbati, R., Zumiani, G., Pagani, W., Malagoli, P. G., Pellicano, R., Donadio, D., Di Vito, C., Cottoni, F., Montesu, M. A., Pirodda, C., Addis, G., Marongiu, P., Farris, A., Cacciapuoti, M., Verrini, A., Desirello, G., Gnone, M., Fimiani, M., Pellegrino, M., Castelli, G., Zappala, L., Sesana, G., Ingordo, V., Vozza, E., Di Giuseppe, D., Fasciocco, D., Nespoli, P., Papini, M., Cicoletti, M., Bernengo, M. G., Ortoncelli, M., Bonvicino, A., Capella, G., Doveil, G. C., Forte, M., Peroni, A., Salomone, B., Savoia, P., Pippione, M., Zichichi, L., Frazzitta, M., De Luca, G., Tasin, L., Simonetto, D., Ros, S., Trevisan, G., Patamia, M., Miertusova, S., Patrone, P., Frattasio, A., Piccirillo, F., La Spina, S., Di Gaetano, L., Marzocchi, V., Motolese, A., Venturi, C., Gai, F., Pasquinucci, S., Bellazzi, R. M., Silvestri, T., Girolomoni, G., Gisondi, P., Veller Fornasa, C., Trevisan, G. P., Damiani G., Cazzaniga S., Conic R.R.Z., Naldi L., Griseta V., Miracapillo A., Azzini M., Mocci L., Michelini M., Offidani A., Bernardini L., Campanati A., Ricotti G., Giacchetti A., Norat M., Gualco F., Castelli A., Cuccia A., Diana A., Roncarolo G., Belli M.A., Baldassarre M.A., Santoro G., Vena G.A., Lo Console F., Filotico R., Mastrandrea V., Brunetti B., Musumeci F., Carrabba E., Dal Mas P., Annicchiarico F., Benvegnu B., Spaziani G., Cusano F., Saletta Iannazzone S., Galluccio A., Pezza M., Marchesi L., Imberti G., Reseghetti A., Barbera C., Reggiani M., Lanzoni A., Patrizi A., Bardazzi F., Antonucci A., De Tommaso S., Wallnofer W., Ingannamorte F., Calzavara-Pinton P., Iannazzi S., Zane C., Capezzera R., Bassisi S., Rossi M.T., Altamura V., Vigl W., Nobile C., Aste N., Murgia S., Mugheddu C., Scuderi G., Baglieri F., Di Dio C., Cilioni Grilli E., Mastronardi C., Agnusdei C.P., Antrilli A., Aulisa L., Raimondo U., Scotto di Luzio G., Battarra V.C., Farro P., Plaitano R., Micali G., Musumeci M.L., Massimino D., Li Calzi M., La Greca S., Pettinato M., Sapienza G., Valenti G., De Giacomo P.F., Amico, Arcangeli F., Brunelli D., Ghetti E., Tulli A., Assi G., Amerio P., Laria G., Prestinari F., Spadafora S., Coppola M., Caresana G., Pezzarossa E., Felisi C., Donato L., Bertero M., Musso L., Pa lazzini S., Bruscino P., Agozzino U.C., Ottaviani M., Simoncini C., Virgili A., Osti F., Fabbri P., Volpi W., Caproni M., Lotti T., Prignano F., Buggiani G., Troiano M., Fenizi G., Altobella A., Amoruso A., Condello M., Goffredo A., Righini M.G., Alessandrini F., Satolli F., Zampetti M., Bertani E., Fossati S., Parodi A., Burlando M., Fiorucci C., Nigro A., Ghigliotti G., Massone L., Moise G.M., Serrai M., Cannata G., Campagnoli A.M., Daly M., Leporati C., Peila R., Filosa G., Bugatti L., Nicolini M., Nazzari G., Cestari R., Anastasio F., Larussa F.M., Pollice N., De Francesco F., Mazzocchetti G., Peris K., Fargnoli M.C., Di Cesare A., De Angelis L., Flati G., Biamonte A.S., Quarta G., Congedo M., Carcaterra A., Strippoli D., Fideli D., Marsili F., Celli M., Ceccarini M., Bachini L., D'Oria M., Schirripa V., De Filippi C., Martini P., Lapucci E., Mazzatenta C., Ghilardi A., Simonacci M., Bettacchi A., Gasco R., Zanca A., Battistini S., Dattola S., Vernaci R., Postorino F., Zampieri P.F., Padovan C., Gonzalez Intchaurraga M.A., Ladurner J., Guarneri B., Cannavo S., Manfre C., Borgia F., Puglisi Guerra A., Cattaneo A., Carrera C., Fracchiolla C., Mozzanica N., Prezzemolo L., Menni S., Lodi A., Martino P., Monti M., Mancini L., Sacrini F., Altomare G.F., Taglioni M., Lovati C., Mercuri S.R., Schiesari G., Giannetti A., Conti A., Lasagni C., Greco M., Ronsini G., Schianchi S., Fiorentini C., Niglietta S., Maglietta R., Padalino C., Crippa D., Pini M., Rossi E., Tosi D., Armas M., Ruocco V., Ayala F., Balato N., Gaudiello F., Cimmino G.F., Monfrecola G., Gallo L., Argenziano G., Fulgione E., Berruti G., Ceparano S., De Michele I., Giorgiano D., Leigheb G., Deledda S., Peserico A., Alaibac M., Piaserico S., Schiesari L., Dan G., Mattei I., Oro E., Arico M., Bongiorno M.R., Angileri R., Amato S., Todaro F., Milioto M., Bellastro R., Di Nuzzo S., De Panfilis G., Zanni M., Borroni G., Cananzi R., Brazzelli V., Lisi P., Stingeni L., Hansel K., Pierfelice V., Donelli S., Rastelli D., Gasperini M., Barachini P., Cecchi R., Bartoli L., Pavesi M., De Paola S., Corradin M.T., Ricciuti F., Piccirillo A., Viola L., Tataranni M., Mautone M.G., Lo Scocco G., Niccoli M.C., Brunasso Vernetti A.M.G., Gaddoni G., Resta F., Casadio M.C., Arcidiaco M.C., Luvara M.C., Albertini G., Di Lernia V., Guareschi E., Catrani S., Morri M., De Simone C., D'Agostino M., Agostino I., Calvieri S., Cantoresi F., Richetta A., Sorgi P., Carnevale C., Nicolucci F., Berardesca E., Ardigo M., De Felice C., Gubinelli E., Talamonti M., Camplone G., Cruciani G., Riccardi F., Barbati R., Zumiani G., Pagani W., Malagoli P.G., Pellicano R., Donadio D., Di Vito C., Cottoni F., Montesu M.A., Pirodda C., Addis G., Marongiu P., Farris A., Cacciapuoti M., Verrini A., Desirello G., Gnone M., Fimiani M., Pellegrino M., Castelli G., Zappala L., Sesana G., Ingordo V., Vozza E., Di Giuseppe D., Fasciocco D., Nespoli P., Papini M., Cicoletti M., Bernengo M.G., Ortoncelli M., Bonvicino A., Capella G., Doveil G.C., Forte M., Peroni A., Salomone B., Savoia P., Pippione M., Zichichi L., Frazzitta M., De Luca G., Tasin L., Simonetto D., Ros S., Trevisan G., Patamia M., Miertusova S., Patrone P., Frattasio A., Piccirillo F., La Spina S., Di Gaetano L., Marzocchi V., Motolese A., Venturi C., Gai F., Pasquinucci S., Bellazzi R.M., Silvestri T., Girolomoni G., Gisondi P., Veller Fornasa C., and Trevisan G.P.

Subjects
Male, Cross-sectional study, Severity of Illness Index, Cohort Studies, 030207 dermatology & venereal diseases, 0302 clinical medicine, Risk Factors, education, itch, pruritus, psoriasis, pustular psoriasis, treatment, Adolescent, Adult, Cross-Sectional Studies, Educational Status, Facial Dermatoses, Female, Foot Dermatoses, Genitalia, Hand Dermatoses, Humans, Italy, Middle Aged, Pruritus, Psoriasis, Registries, Sex Factors, Young Adult, Epidemiology, Young adult, skin and connective tissue diseases, Settore MED/33 - MALATTIE APPARATO LOCOMOTORE, Infectious Diseases, 030220 oncology & carcinogenesis, Cohort, PRURITIS EPIDEMIOLOGY, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Cohort study, medicine.medical_specialty, PSORIAS, Dermatology, Article, 03 medical and health sciences, Pharmacotherapy, Settore MED/35, Severity of illness, medicine, business.industry, medicine.disease, Pruritus,Itch sensation, business
Abstract

Background: Psoriasis (Ps) is a chronic systemic autoimmune disease associated with pruritus in 64–98% of patients. However, few modestly sized studies assess factors associated with psoriatic pruritus. Objective: To investigate factors associated with Ps pruritus intensity. Methods: Psoriasis patients 18years or older seen in one of 155 centres in Italy between September 2005 and 2009 were identified from the Italian PsoCare registry. Patients without cutaneous psoriasis and those with missed information on pruritus were excluded. Results: We identified 10802 patients, with a mean age 48.8±14.3years. Mild itch was present in 33.2% of patients, moderate in 34.4%, severe in 18.7% and very severe in 13.7%. Higher itch intensity was associated with female gender, lower educational attainment compared to university degree, pustular psoriasis, psoriasis on the head, face, palmoplantar areas, folds and genitalia, more severe disease, disease duration

Published
2019

20. Chilblain‐like lesions during COVID‐19 epidemic: a preliminary study on 63 patients

Author

Piccolo, V., primary, Neri, I., additional, Filippeschi, C., additional, Oranges, T., additional, Argenziano, G., additional, Battarra, V.C., additional, Berti, S., additional, Manunza, F., additional, Fortina, A.B., additional, Di Lernia, V., additional, Boccaletti, V., additional, De Bernardis, G., additional, Brunetti, B., additional, Mazzatenta, C., additional, and Bassi, A., additional

Published
2020
Full Text
View/download PDF

22. COVID vaccine‐induced lichen planus on areas previously affected by vitiligo.

Author

Piccolo, V., Mazzatenta, C., Bassi, A., Argenziano, G., Cutrone, M., Grimalt, R., and Russo, T.

Subjects
*LICHEN planus, *VITILIGO, *COVID-19, *COVID-19 vaccines, *SKIN diseases
Abstract

The patient mentioned in this manuscript has given written informed consent for the publication of her case details. GLO:3NZ/01jan22:jdv17687-fig-0001.jpg PHOTO (COLOR): 1 Lichen planus exclusively localized on pre-existing vitiligo patches of the hands. gl GLO:3NZ/01jan22:jdv17687-fig-0002.jpg PHOTO (COLOR): 2 Dermoscopy showing the typical Wickham striae of lichen planus. gl Even if uncommon, the co-occurrence of LP on vitiligo is certainly not new, as several reports are present in the literature.1-3 In most cases, LP appeared after vitiligo, although concurrent diseases or LP preceding vitiligo have been reported. COVID vaccine-induced lichen planus on areas previously affected by vitiligo. [Extracted from the article]

Published
2022
Full Text
View/download PDF

23. Latent tubercolosis infection in patients with cronic plaque psoriasis: evidence from the Italian Psocare Registry

Author

Gisondi, P, Cazzaniga, S, Chimenti, S, Maccarone, M, Picardo, M, Girolomoni, G, Naldi, L, Griseta V, Psocare Study Group., Miracapillo, A, Azzini, M, Mocci, L, Michelini, M, Offidani, A, Bernardini, L, Campanati, A, Ricotti, G, Giacchetti, Alessandro, Norat, M, Gualco, F, Castelli, A, Cuccia, A, Diana, A, Roncarolo, G, Belli, Ma, Baldassarre, Ma, Santoro, G, Vena, Ga, Lo Console, F, Filotico, R, Mastrandrea, V, Brunetti, B, Musumeci, F, Carrabba, E, Dal Mas, P, Annicchiarico, F, Benvegnù, B, Spaziani, G, Cusano, F, Saletta Iannazzone, S, Galluccio, A, Pezza, M, Marchesi, L, Imberti, G, Reseghetti, A, Barbera, Claudia, Reggiani, Matteo, Lanzoni, A, Patrizi, A, Bardazzi, F, Antonucci, A, De Tommaso, S, Balestri, R, Wallnofer, W, Ingannamorte, F, Calzavara-Pinton, P, Iannazzi, S, Zane, C, Capezzera, R, Bassisi, S, Rossi, Mt, Altamura, V, Vigl, W, SCHETTINO NOBILE, Carla, Aste, N, Murgia, S, Mugheddu, C, Scuderi, G, Baglieri, F, Di Dio, C, Cilioni Grilli, E, Mastronardi, C, Agnusdei, Cp, Antrilli, A, Aulisa, L, Raimondo, U, Scotto di Luzio, G, Battarra, Vc, Farro, P, Plaitano, R, Micali, G, Musumeci, Ml, D'Armiento, Massimino, Li Calzi, M, LA GRECA, SEBASTIANO VITTORIO, Pettinato, Cristiana Maria, Sapienza, G, Valenti, G, De Giacomo PF, D'Amico, D, Arcangeli, Federica, Brunelli, D, Ghetti, E, Tulli, Augusta, Assi, G, Amerio, P, Laria, G, Prestinari, F, Spadafora, S, Coppola, M, Caresana, G, Pezzarossa, E, Domaneschi, E, Felisi, C, Donato, L, Bertero, M, Musso, L, Pa Lazzini, S, Bruscino, P, Agozzino, Uc, Ottaviani, M, Simoncini, Cristiana, Virgili, A, Osti, F, Fabbri, P, Volpi, Walter, Caproni, M, Lotti, T, Prignano, F, Buggiani, G, Troiano, M, Fenizi, G, Altobella, A, Amoruso, A, Condello, M, Goffredo, A, Righini, Mg, Alessandrini, F, Satolli, F, Zampetti, M, Bertani, E, Fossati, S, Parodi, A, Burlando, M, Fiorucci, C, Nigro, A, Ghigliotti, G, Massone, L, Moise, Gm, Serrai, M, Cannata, G, Campagnoli, Am, Daly, M, Leporati, C, Peila, R, Filosa, Giovanna, Bugatti, L, Nicolini, M, Nazzari, G, Cestari, R, Anastasio, Fabio, Larussa, Fm, Pollice, N, De Francesco, F, Mazzocchetti, G, Peris, K, Fargnoli, Mc, Di Cesare, A, De Angelis, L, Flati, G, Biamonte, As, Quarta, Giovanni, Congedo, M, Carcaterra, A, Strippoli, D, Fideli, D, Marsili, Filippo, Celli, M, Ceccarini, M, Bachini, L, D ORIA, MARIA FEDERICA, Schirripa, V, De Filippi, C, Martini, P, Lapucci, E, Mazzatenta, C, Ghilardi, A, Simonacci, M, Bettacchi, A, Gasco, R, Zanca, A, Battistini, Simone, Dattola, S, Vernaci, R, Postorino, F, Zampieri, Pf, Padovan, MARIA CRISTINA, González Intchaurraga MA, Ladurner, J, Guarneri, B, Cannavo', Serena, Manfrè, C, Borgia, F, Puglisi Guerra, A, Sedona, P, Cattaneo, A, Carrera, C, Fracchiolla, C, Mozzanica, N, Prezzemolo, L, Menni, S, Lodi, A, Martino, P, Monti, M, Mancini, L, Sacrini, F, Altomare, Gf, Taglioni, M, Lovati, C, Mercuri, Sr, Schiesari, G, Giannetti, A, Conti, A, Lasagni, C, Greco, M, Ronsini, G, Schianchi, S, Fiorentini, C, Niglietta, S, Miglietta, R, Padalino, C, Crippa, D, Pini, M, Rossi, E, Tosi, D, Armas, M, Ruocco, V, Ayala, F, Balato, N, Gaudiello, F, Cimmino, Gf, Monfrecola, G, Gallo, L, Argenziano, G, Fulgione, E, Berruti, G, Mozzillo, R, Ceparano, S, De Michele, I, Giorgiano, D, Leigheb, G, Deledda, S, Peserico, A, Alaibac, M, Piaserico, S, Schiesari, L, Dan, G, Mattei, I, Oro, E, Aricò, M, Bongiorno, Mr, Angileri, Rosalia, Amato, S, Todaro, F, Milioto, M, Bellastro, R, Di Nuzzo, S, De Panfilis, G, Zanni, M, Borroni, G, Cananzi, R, Brazzelli, V, Lisi, P, Stingeni, L, Hansel, K, Pierfelice, V, Donelli, S, Rastelli, D, Gasperini, M, Barachini, P, Cecchi, R, Bartoli, L, Pavesi, Maria Gabriella, De Paola, S, Corradin, Mt, Ricciuti, F, Piccirillo, Alessandro, Viola, L, Tataranni, M, Mautone, Mg, Lo Scocco, G, Niccoli, Mc, Brunasso Vernetti AM, Gaddoni, G, DI RESTA, Fabio, Casadio, Mc, Arcidiaco, Mc, Luvarà, Mc, ALBERTINI PETRONI, Guglielmo, DI LERNIA, Valerio, Guareschi, E, Catrani, S, Morri, M, De Simone, C, D'Agostino, M, Agostino, I, Calvieri, S, Cantoresi, F, Richetta, A, Sorgi, Paola, Carnevale, C, Nicolucci, F, Berardesca, E, Ardigò, M, De Felice, C, Gubinelli, E, Talamonti, Marina, Camplone, G, Cruciani, Giulio, Riccardi, F, Barbati, R, Zumiani, G, Pagani, W, Malagoli, Pg, Pellicano, R, Donadio, Diego, Di Vito, C, Cottoni, F, Montesu, Ma, Pirodda, C, Addis, G, Marongiu, P, Farris, A, Cacciapuoti, Anna Maria, Verrini, A, Desirello, G, Gnone, M, Fimiani, M, Pellegrino, M, Castelli, G, Zappalà, L, Sesana, G, Ingordo, V, Vozza, E, Di Giuseppe, D, Fasciocco, D, Nespoli, P, Papini, M, Cicoletti, M, Bernengo, Mg, Ortoncelli, M, Bonvicino, A, Capella, G, Doveil, Gc, Forte, M, Peroni, A, Salomone, B, Savoia, P, Pippione, M, Zichichi, Ludovica, Frazzitta, M, De Luca, G, Tasin, L, Simonetto, D, Ros, S, Trevisan, G, Patamia, M, Miertusova, S, Patrone, Pietro, Frattasio, A, Piccirillo, Fabiola, La Spina, S, Di Gaetano, L, Marzocchi, V, Motolese, A, Venturi, Caterina, Gai, Francesco, Pasquinucci, S, Bellazzi, Rm, Silvestri, Tommaso, Veller Fornasa, C, Trevisan, Gp., Gisondi, P, Cazzaniga, S, Chimenti, S, Maccarone, M, Picardo, M, Girolomoni, G, Naldi, L, the Psocare Study Group [.., Annalisa Patrizi, ], Trevisan, Giusto, Girolomoni, G., Maccarone, Sergio, Naldi, L., Gisondi, P., Cazzaniga, S., Chimenti, S., Maccarone, M., Picardo, M., Griseta, V., Miracapillo, A., Azzini, M., Mocci, L., Michelini, M., Offidani, A., Bernardini, L., Campanati, A., Ricotti, G., Giacchetti, A., Norat, M., Gualco, F., Castelli, A., Cuccia, A., Diana, A., Roncarolo, G., Belli, M.A., Baldassarre, M.A., Santoro, G., Vena, G.A., Lo Console, F., Filotico, R., Mastrandrea, V., Brunetti, B., Musumeci, F., Carrabba, E., Dal Mas, P., Annicchiarico, F., Benvegnù, B., Spaziani, G., Cusano, F., Saletta Iannazzone, S., Galluccio, A., Pezza, M., Marchesi, L., Imberti, G., Reseghetti, A., Barbera, C., Reggiani, M., Lanzoni, A., Patrizi, A., Bardazzi, F., Antonucci, A., De Tommaso, S., Balestri, R., Wallnofer, W., Ingannamorte, F., Calzavara-Pinton, P., Iannazzi, S., Zane, C., Capezzera, R., Bassisi, S., Rossi, M.T., Altamura, V., Vigl, W., Nobile, C., Aste, N., Murgia, S., Mugheddu, C., Scuderi, G., Baglieri, F., Di Dio, C., Cilioni Grilli, E., Mastronardi, C., Agnusdei, C.P., Antrilli, A., Aulisa, L., Raimondo, U., Scotto Di Luzio, G., Battarra, V.C., Farro, P., Plaitano, R., Micali, G., Musumeci, M.L., Massimino, D., Li Calzi, M., La Greca, S., Pettinato, M., Sapienza, G., Valenti, G., De Giacomo, P.F., D'Amico, D., Arcangeli, F., Brunelli, D., Ghetti, E., Tulli, A., Assi, G., Amerio, P., Laria, G., Prestinari, F., Spadafora, S., Coppola, M., Caresana, G., Pezzarossa, E., Domaneschi, E., Felisi, C., Donato, L., Bertero, M., Musso, L., Pa Lazzini, S., Bruscino, P., Agozzino, U.C., Ottaviani, M., Simoncini, C., Virgili, A., Osti, F., Fabbri, P., Volpi, W., Caproni, M., Lotti, T., Prignano, F., Buggiani, G., Troiano, M., Fenizi, G., Altobella, A., Amoruso, A., Condello, M., Goffredo, A., Righini, M.G., Alessandrini, F., Satolli, F., Zampetti, M., Bertani, E., Fossati, S., Parodi, A., Burlando, M., Fiorucci, C., Nigro, A., Ghigliotti, G., Massone, L., Moise, G.M., Serrai, M., Cannata, G., Campagnoli, A.M., Daly, M., Leporati, C., Peila, R., Filosa, G., Bugatti, L., Nicolini, M., Nazzari, G., Cestari, R., Anastasio, F., Larussa, F.M., Pollice, N., De Francesco, F., Mazzocchetti, G., Peris, K., Fargnoli, M.C., Di Cesare, A., De Angelis, L., Flati, G., Biamonte, A.S., Quarta, G., Congedo, M., Carcaterra, A., Strippoli, D., Fideli, D., Marsili, F., Celli, M., Ceccarini, M., Bachini, L., D'Oria, M., Schirripa, V., De Filippi, C., Martini, P., Lapucci, E., Mazzatenta, C., Ghilardi, A., Simonacci, M., Bettacchi, A., Gasco, R., Zanca, A., Battistini, S., Dattola, S., Vernaci, R., Postorino, F., Zampieri, P.F., Padovan, C., González Intchaurraga, M.A., Ladurner, J., Guarneri, B., Cannavò, S.P., Manfrè, C., Borgia, F., Puglisi Guerra, A., Sedona, P., Cattaneo, A., Carrera, C., Fracchiolla, C., Mozzanica, N., Prezzemolo, L., Menni, S., Lodi, A., Martino, P., Monti, M., Mancini, L., Sacrini, F., Altomare, G.F., Taglioni, M., Lovati, C., Mercuri, S.R., Schiesari, G., Giannetti, A., Conti, A., Lasagni, C., Greco, M., Ronsini, G., Schianchi, S., Fiorentini, C., Niglietta, S., Maglietta, R., Padalino, C., Crippa, D., Pini, M., Rossi, E., Tosi, D., Armas, M., Ruocco, V., Ayala, F., Balato, N., Gaudiello, F., Cimmino, G.F., Monfrecola, G., Gallo, L., Argenziano, G., Fulgione, E., Berruti, G., Mozzillo, R., Ceparano, S., De Michele, I., Giorgiano, D., Leigheb, G., Deledda, S., Peserico, A., Alaibac, M., Piaserico, S., Schiesari, L., Dan, G., Mattei, I., Oro, E., Aricò, M., Bongiorno, M.R., Angileri, R., Amato, S., Todaro, F., Milioto, M., Bellastro, R., Di Nuzzo, S., De Panfilis, G., Zanni, M., Borroni, G., Cananzi, R., Brazzelli, V., Lisi, P., Stingeni, L., Hansel, K., Pierfelice, V., Donelli, S., Rastelli, D., Gasperini, M., Barachini, P., Cecchi, R., Bartoli, L., Pavesi, M., De Paola, S., Corradin, M.T., Ricciuti, F., Piccirillo, A., Viola, L., Tataranni, M., Mautone, M.G., Lo Scocco, G., Niccoli, M.C., Brunasso Vernetti, A.M.G., Gaddoni, G., Resta, F., Casadio, M.C., Arcidiaco, M.C., Luvarà, M.C., Albertini, G., Di Lernia, V., Guareschi, E., Catrani, S., Morri, M., De Simone, C., D'Agostino, M., Agostino, I., Calvieri, S., Cantoresi, F., Richetta, A., Sorgi, P., Carnevale, C., Nicolucci, F., Berardesca, E., Ardigò, M., De Felice, C., Gubinelli, E., Talamonti, M., Camplone, G., Cruciani, G., Riccardi, F., Barbati, R., Zumiani, G., Pagani, W., Malagoli, P.G., Pellicano, R., Donadio, D., Di Vito, C., Cottoni, F., Montesu, M.A., Pirodda, C., Addis, G., Marongiu, P., Farris, A., Cacciapuoti, M., Verrini, A., Desirello, G., Gnone, M., Fimiani, M., Pellegrino, M., Castelli, G., Zappalà, L., Sesana, G., Ingordo, V., Vozza, E., Di Giuseppe, D., Fasciocco, D., Nespoli, P., Papini, M., Cicoletti, M., Bernengo, M.G., Ortoncelli, M., Bonvicino, A., Capella, G., Doveil, G.C., Forte, M., Peroni, A., Salomone, B., Savoia, P., Pippione, M., Zichichi, L., Frazzitta, M., De Luca, G., Tasin, L., Simonetto, D., Ros, S., Trevisan, G., Patamia, M., Miertusova, S., Patrone, P., Frattasio, A., Piccirillo, F., La Spina, S., Di Gaetano, L., Marzocchi, V., Motolese, A., Venturi, C., Gai, F., Pasquinucci, S., Bellazzi, R.M., Silvestri, T., Veller Fornasa, C., and Trevisan, G.P.

Subjects
Registrie, Male, taiwan, Antitubercular Agents, Biological Factor, quantiferon-tb-gold, Antitubercular Agent, Biological Factors, experience, Residence Characteristics, 80 and over, Prevalence, Registries, Young adult, risk, Aged, 80 and over, Latent Tuberculosi, Latent tuberculosis, psoriasis, Middle Aged, Italy, Female, tubercolosis, tubercolosi, Adolescent, Adult, Age Distribution, Aged, Chronic Disease, Humans, Latent Tuberculosis, PUVA Therapy, Psoriasis, Sex Distribution, Tuberculin Test, Young Adult, 2708, Human, medicine.drug, medicine.medical_specialty, chronic plaque psoriasis, Tuberculin, consensus statement, Dermatology, tuberculosis infection, Settore MED/35, Internal medicine, medicine, Adalimumab, factor antagonists, necrosis-factor blockers, systemic treatment, therapy, assay, Psoriasi, History of tuberculosis, tuberculosis infection, chronic plaque psoriasis,Italian Psocare Registry, business.industry, Odds ratio, medicine.disease, bacterial infections and mycoses, Confidence interval, Surgery, Residence Characteristic, Italian Psocare Registry, business
Abstract

SummaryBackground The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. Objectives To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Methods Data were obtained from the Psocare Registry on those patients (n = 4946) with age > 18 years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Results Latent tuberculosis infection was diagnosed in 8·3% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4·3% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen–ultraviolet A (P

Published
2015

24. Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus

Author

Chiricozzi, Andrea, Pimpinelli, N., Ricceri, F., Bagnoni, G., Bartoli, L., Bellini, M., Brandini, L., Caproni, M., Castelli, A., Fimiani, M., Marsili, F., Mazzatenta, C., Niccoli, M. C., Panduri, S., Pellegrino, M., Sirna, R., Volpi, W., Romanelli, M., Prignano, F., Chiricozzi A. (ORCID:0000-0002-6739-0387), Chiricozzi, Andrea, Pimpinelli, N., Ricceri, F., Bagnoni, G., Bartoli, L., Bellini, M., Brandini, L., Caproni, M., Castelli, A., Fimiani, M., Marsili, F., Mazzatenta, C., Niccoli, M. C., Panduri, S., Pellegrino, M., Sirna, R., Volpi, W., Romanelli, M., Prignano, F., and Chiricozzi A. (ORCID:0000-0002-6739-0387)

Abstract

Psoriasis is a chronic and relapsing inflammatory skin disease, clinically characterized by erythematous and scaly plaques. Treatment approach is mainly driven by disease severity, though several factors should be considered in order to identify the optimal therapeutic choice. Mild psoriasis may be treated with a wide array of topical agents including corticosteroids, vitamin D analogs, keratolytics, and calcipotriol/betamethasone propionate compound. Because guidelines may not provide practical indications regarding the therapeutic approach, the use of topical agents in psoriasis is more individually tailored. In order to homogenize the standard of care, at least in a local setting, we collected the real-life-based recommendations for the use of topical therapies from an expert panel, the Tuscany Consensus Group on Psoriasis, representing all leading centers for psoriasis established in Tuscany. With this document, this consensus group sought to define principles guiding the selection of therapeutic agents with straightforward recommendations derived from a real-life setting.

Published
2017

27. Dermoscopy of chilblain-like lesions during the COVID-19 outbreak: A multicenter study on 10 patients

Author

Carlo Mazzatenta, Andrea Bassi, Iria Neri, Vincenzo Piccolo, Alba Guglielmo, Annalisa Patrizi, Giuseppe Argenziano, Piccolo, V., Bassi, A., Argenziano, G., Mazzatenta, C., Guglielmo, A., Patrizi, A., Neri, I., Piccolo V., Bassi A., Argenziano G., Mazzatenta C., Guglielmo A., Patrizi A., and Neri I.

Subjects
Male, 2019-20 coronavirus outbreak, Letter, Chilblain, Adolescent, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Dermoscopy, Dermatology, Betacoronavirus, Young Adult, Pandemic, Humans, Medicine, Child, Chilblains, Pandemics, Skin, Betacoronaviru, biology, Coronavirus Infection, SARS-CoV-2, business.industry, COVID-19, Outbreak, biology.organism_classification, medicine.disease, Virology, Multicenter study, Female, Coronavirus Infections, business, Human
Published
2020
Full Text
View/download PDF

29. Oral cinnarizine for the treatment of COVID‐19‐associated <scp>chilblain‐like</scp> lesions: An old drug for a new disease?

Author

Carlo Mazzatenta, Vincenzo Piccolo, Giuseppe Argenziano, Andrea Bassi, Mazzatenta, C., Piccolo, V., Argenziano, G., and Bassi, A.

Subjects
Chilblains, Cinnarizine, SARS-CoV-2, COVID-19, Humans, chilblain-like lesion, Dermatology, General Medicine, Pandemics, COVID-19 Drug Treatment
Abstract

During SARS-CoV-2 pandemic, an outbreak of chilblain-like lesions has been developed, even if the relationship with the virus infection is still debated. We report the good results obtained in 12 patients with chilblain lesions and the use of oral cinnarizine, a piperazine derivative with many pharmacological properties among whom antihistaminic and calcium channel blocking activities.

Published
2022
Full Text
View/download PDF

31. Face mask-induced purpura: another unexpected effect of COVID era

Author

V. Piccolo, A. Bassi, C. Mazzatenta, T. Russo, G. Argenziano, M. Cutrone, Markus ES Danielsson Darlington, R. Grimalt, Piccolo, V., Bassi, A., Mazzatenta, C., Russo, T., Argenziano, G., Cutrone, M., Danielsson Darlington, M. E. S., and Grimalt, R.

Subjects
Infectious Diseases, SARS-CoV-2, Masks, Humans, COVID-19, Dermatology, Personal Protective Equipment, Purpura
Published
2022

32. COVID vaccine-induced lichen planus on areas previously affected by vitiligo

Author

Ramon Grimalt, Andrea Bassi, Carlo Mazzatenta, Mario Cutrone, Vincenzo Piccolo, Teresa Russo, Giuseppe Argenziano, Piccolo, V., Mazzatenta, C., Bassi, A., Argenziano, G., Cutrone, M., Grimalt, R., and Russo, T.

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Vitiligo, Dermatology, Letters To The Editor, Lesion, medicine, Humans, Letter to the Editor, Hypopigmentation, Vaccines, integumentary system, business.industry, SARS-CoV-2, Lichen Planus, COVID-19, medicine.disease, Infectious Diseases, Sun exposure, medicine.symptom, business
Abstract

We recently came across a 64-year-old woman who developed pruritic papules on both hands previously affected by vitiligo since 30 years earlier. The lesion firstly appeared 5 days after the first dose of BNT162b2 mRNA COVID-19 Vaccine, then faded away, thus recurring 24 hours soon after the second dose with a more extensive and symptomatic eruption. The patient noticed and referred a worsening of skin condition after sun exposure.

Published
2021

33. Contemporary occurrence of Chilblain‐like lesions and Pityriasis rosea during the COVID‐19 pandemic

Author

Giuseppe Argenziano, Carlo Mazzatenta, Ramon Grimalt, Mario Cutrone, Teresa Russo, Iria Neri, Vincenzo Piccolo, Andrea Bassi, Piccolo, V., Bassi, A., Argenziano, G., Mazzatenta, C., Cutrone, M., Neri, I., Grimalt, R., and Russo, T.

Subjects
0301 basic medicine, 2019-20 coronavirus outbreak, medicine.medical_specialty, Pityriasis Rosea, Chilblain, Coronavirus disease 2019 (COVID-19), media_common.quotation_subject, Dermatology, medicine.disease_cause, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Pandemic, medicine, Humans, Girl, Chilblains, Letters to the Editor, Letter to the Editor, Pandemics, media_common, Coronavirus, business.industry, SARS-CoV-2, COVID-19, medicine.disease, Trunk, 030104 developmental biology, Infectious Diseases, Pityriasis rosea, business, Human
Abstract

During the second wave of infection, we came across an otherwise healthy 12-year-old girl with a 3-week history of erythematous-edematous and ulcerated lesions of the toes (Figure 1), compatible with the diagnosis of CLL. Similar lesions already appeared during the first wave of March-April 2020 and resolved spontaneously in 3 months. Apart from CLL, the patient contemporarily developed a classical mildly itchy pityriasis rosea (PR) on the trunk (Figure 2), that was the major reason of complaint in this occasion.

Published
2021

34. BNT162b2 mRNA COVID‐19 vaccine‐induced chilblain‐like lesions reinforces the hypothesis of their relationship with SARS‐CoV‐2

Author

Teresa Russo, Iria Neri, Giuseppe Argenziano, Andrea Bassi, Carlo Mazzatenta, Vincenzo Piccolo, Ramon Grimalt, Mario Cutrone, Piccolo, V., Bassi, A., Argenziano, G., Mazzatenta, C., Cutrone, M., Neri, I., Grimalt, R., and Russo, T.

Subjects
0301 basic medicine, 2019-20 coronavirus outbreak, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19 Vaccine, Dermatology, medicine.disease_cause, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Medicine, Humans, RNA, Messenger, Chilblains, Letters to the Editor, Letter to the Editor, BNT162 Vaccine, Coronavirus, Messenger RNA, business.industry, SARS-CoV-2, RNA, COVID-19, medicine.disease, Virology, 030104 developmental biology, Infectious Diseases, business, Human
Published
2021

35. Chilblain-like lesions and COVID-19: second wave, second outbreak

Author

Maura Baraldi, Carlo Mazzatenta, Mario Cutrone, Iria Neri, Giuseppe Argenziano, Vincenzo Piccolo, Teresa Russo, Andrea Bassi, Piccolo, V., Bassi, A., Russo, T., Mazzatenta, C., Baraldi, M., Argenziano, G., Neri, I., and Cutrone, M.

Subjects
2019-20 coronavirus outbreak, Disease Outbreak, Coronavirus disease 2019 (COVID-19), business.industry, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Outbreak, COVID-19, Dermatology, medicine.disease, medicine.disease_cause, Virology, Disease Outbreaks, Chilblains, Infectious Diseases, medicine, Humans, Letters to the Editor, business, Letter to the Editor, Coronavirus, Human
Published
2021

36. Chilblain-like lesions during COVID-19 pandemic: The state of the art

Author

Elisabetta Venturini, Andrea Bassi, Teresa Russo, Giuseppe Argenziano, Carlo Mazzatenta, Iria Neri, Vincenzo Piccolo, Bassi, A., Russo, T., Argenziano, G., Mazzatenta, C., Venturini, E., Neri, I., and Piccolo, V.

Subjects
Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Chilblain-like lesion, Paleontology, COVID-19, Disease cluster, Skin manifestation, General Biochemistry, Genetics and Molecular Biology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Geography, Space and Planetary Science, Pandemic, Perspective, lcsh:Q, 030212 general & internal medicine, chilblain-like lesions, lcsh:Science, Ecology, Evolution, Behavior and Systematics, Demography
Abstract

SARS-CoV-2 infection has spread all over the world in the last year, causing millions of COVID-19 cases among humans with a large variability of symptoms and signs, including those on the skin. Among these, a contemporary cluster of chilblain-like lesions with no certain relationship with the infection has been reported. The aim of this paper is to delineate a profile of chilblain-like lesions and to establish the state-of-the-art knowledge about this new phenomenon.

Published
2021

37. Tuscany consensus for pediatric scabies: update on clinical management and the urgent need for new guidelines.

Author

Bassi A, Magnano M, Filippeschi C, Berti S, Bachini L, Vispi M, Peccianti C, Coronella G, Oranges T, and Mazzatenta C

Abstract

Background: The aim of this study was to assess the degree of agreement among pediatric dermatologists in Tuscany concerning different aspects of scabies infestation management in children, employing the Delphi method., Methods: We conducted a Delphi study involving ten pediatric dermatology centers in Tuscany, Italy. Questionnaires were distributed to a panel of experts anonymously. The questionnaires were organized into six specific topics: "diagnosis," "hygiene measures," "application of topical products," "treatment," "treatment of exposed individuals," and "clinical follow-up after therapy." Each question within these topics offered six different response options., Results: All participating dermatologists completed the two-round questionnaire. Full consensus was reached for all statements related to "diagnosis," "hygiene measures," "treatment of exposed individuals," "application of topical products," and "clinical follow-up after therapy," since each statement met the predetermined consensus threshold of 70% or higher. However, we could not achieve a substantial consensus on the treatment of scabies, aside from agreement on the lower efficacy of permethrin therapy., Conclusions: Considering the growing recognition of Sarcoptes scabiei resistance to conventional permethrin therapy, this regional consensus offers clear insights into the overall management of scabies. However, it also reveals that each dermatologist primarily relies on their own experiences for medical treatment, which may not be universally shared among colleagues. This emphasizes the urgent necessity for updated guidelines on therapeutic strategies.

Published
2024
Full Text
View/download PDF

39. Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum.

Author

Salvia G, Bevilacqua M, Manzo Margiotta F, Michelucci A, Granieri G, Fidanzi C, Dini V, Romanelli M, and Mazzatenta C

Subjects
Humans, Female, Drug Substitution, Middle Aged, Male, Psoriasis drug therapy, Dermatologic Agents adverse effects, Dermatologic Agents therapeutic use, Pyoderma Gangrenosum chemically induced, Pyoderma Gangrenosum drug therapy, Adalimumab adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use
Published
2024
Full Text
View/download PDF

41. Congenital Cutaneous Candidiasis with Nail Involvement.

Author

Tuoni C, Mazzatenta C, and Filippi L

Subjects
Infant, Newborn, Humans, Nails, Skin, Candidiasis diagnosis, Candidiasis drug therapy, Nail Diseases
Abstract

Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest.

Published
2023
Full Text
View/download PDF

42. Pso-Reg: a web registry for psoriasis in real life.

Author

Trovato E, Cartocci A, Calabrese L, D'Onghia M, Dragotto M, Capalbo E, Silvi G, Manzo Margiotta F, Pimpinelli N, Pellegrino M, Romanelli M, Dini V, Cuccia A, Mazzatenta C, Rubegni P, and Prignano F

Subjects
Humans, Retrospective Studies, Comorbidity, Registries, Psoriasis therapy, Psoriasis drug therapy, Arthritis, Psoriatic drug therapy
Abstract

Background: Psoriasis (PsO) is a common immune mediated inflammatory disease, affecting about 60 million people worldwide. Although current therapies have dramatically changed the therapeutic approach to the disease, the heterogeneity of responses often results in an essential unmet clinical need. This study describes the design and development of the Psoriasis Registry (Pso-Reg), an Italian electronic-based-registry, aimed to collect real life data of patients with psoriasis., Methods: Pso-Reg is a multicenter, retrospective and observational cohort study based on the Research Electronic Data Capture (REDcap) tool. Five Italian medical centres were part of the network and all patients affected by PsO were included in the study. Socio-demographic, clinical characteristics, laboratory findings and therapies were collected, and descriptive analysis was carried out., Results: Among the 768 patients analyzed, 446 were men (58.1%), with a mean age of 55.5 years. The first more frequent comorbidity was psoriatic arthritis (26.8%), followed by hypertension (25.3%), diabetes (10%) and dyslipidemia (11.7%). Of the entire cohort, 240 patients (38.2%) had a positive family history for PsO. Vulgar type was the most common phenotype (85.5%), with a major involvement of the scalp (13.8%). The mean PASI (Psoriasis Area Severity Index) score at the baseline was 7.5 (7.8). At the enrolment, 107 patients were treated with topic treatments (13.9%), 5 with phototherapy (0.7%), 92 with cDMARDs (conventional disease-modifying anti-rheumatic drugs) (12.0%) and 471 with biologic therapies (61.3%)., Conclusions: Real-life data from Pso-Reg could contribute providing the rationale for an individual-based strategy and a more tailored approach for the management of psoriasis.

Published
2023
Full Text
View/download PDF

43. "One-shot" combined therapy with oral ivermectin and local benzyl benzoate: is the current best therapeutic option in the era of permethrin resistant scabies?

Author

Bassi A, Piccolo V, and Mazzatenta C

Subjects
Humans, Permethrin therapeutic use, Benzoates therapeutic use, Administration, Oral, Ivermectin therapeutic use, Scabies drug therapy
Abstract

Competing Interests: Declaration of competing interest All the authors have no financial obligations or conflict of interest to declare.

Published
2023
Full Text
View/download PDF

45. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.

Author

Prignano F, Pescitelli L, Trovato E, DI Cesare A, Cuccia A, Mazzatenta C, Pellegrino M, Marsili F, Castelli A, Brandini L, Niccoli MC, Taviti F, Ricceri F, Panduri S, Buggiani G, Ghilardi A, Rubegni P, Romanelli M, and Pimpinelli N

Subjects
Humans, Biological Factors therapeutic use, Consensus, Interleukin-23 therapeutic use, Quality of Life, Tumor Necrosis Factor Inhibitors therapeutic use, Interleukin-17 immunology, Biological Products therapeutic use, Psoriasis drug therapy
Abstract

Psoriasis is a common chronic skin disease characterized by a worldwide distribution and a natural tendency towards progression. According to the many clinical forms, the extension of the disease and the many comorbidities, almost the 20% of the patients require a systemic treatment. Biologics have greatly changed the ongoing of psoriasis and the quality of life of psoriasis patients. After the anti-TNF-alpha, which were the first biologics in use for psoriasis, the improvement in knowledge of the pathogenetic mechanisms underlying the disease has led to the development of a series of more specific therapies for psoriasis. This "second generation" of biologics includes the interleukin (IL)-12/23 inhibitor ustekinumab, IL-17 inhibitors (secukinumab and ixekizumab), the IL-17 receptor A (IL-17RA) antagonist brodalumab, and the IL-23 inhibitors guselkumab, risankizumab and tildrakizumab. This study represents an update of the Tuscany consensus focused on the use of new drugs, such as anti-IL-17 and anti-IL-23 in moderate-to-severe psoriasis and their correct place in therapy according to specific clinical requests and in full respect of the current financial restrictions.

Published
2022
Full Text
View/download PDF

46. Human monkeypox Italian locoregional small cluster.

Author

Bassi A, Piccolo V, de Gennaro M, Simoni B, and Mazzatenta C

Subjects
Animals, Humans, Zoonoses, Mpox, Monkeypox epidemiology
Abstract

Competing Interests: Declaration of competing interest All the authors have no financial obligations or conflict of interest to declare.

Published
2022
Full Text
View/download PDF

48. Update on the Management of Pediatric Psoriasis: An Italian Consensus.

Author

Peris K, Fortina AB, Bianchi L, Fabbrocini G, Gisondi P, Balato A, Bardazzi F, Bernardini N, Bonamonte D, Bongiorno MR, Buligan C, Cusano F, Del Giudice MBF, El Hachem M, Fargnoli MC, Gualdi G, Guarneri C, Hansel K, Malara G, Mazzatenta C, Micali G, Narcisi A, Neri I, Oranges T, Panzone M, Parodi A, Restano L, Simonetti O, Venturini M, and Di Lernia V

Abstract

Introduction: Psoriasis affects children with a considerable burden in early life. Treating pediatric psoriasis is challenging also because of the lack of updated specific guidelines. With the recent approval of several biologics for pediatric psoriasis and the ongoing COVID-19 pandemic, the management of young psoriatic patients is facing major changes. A revision of treatment recommendations is therefore needed., Methods: In September 2021, a board of six Italian dermatologists convened to update treatment recommendations. The board issued evidence- and consensus-based statements covering relevant areas of pediatric psoriasis, namely: assessment of psoriasis severity, management of children with psoriasis, and treatment of pediatric psoriasis. To reach consensus, the statements were submitted to a panel of 24 experts in a Delphi process performed entirely via videoconference. A treatment algorithm was produced., Results: There was full consensus that psoriasis severity is determined by the extension/severity of skin lesions, site of lesions, and impact on patient quality of life. Agreement was reached on the need for a multidisciplinary approach to pediatric psoriasis and the importance of patient/parents education. The relevance of vaccinations, including COVID-19 vaccination, for psoriatic children was acknowledged by all participants. Management issues that initially failed to reach consensus included the screening for psoriasis comorbidities and early treatment with biologics to prevent them and the use of telemedicine to facilitate patient follow-up. There was full consensus that topical corticosteroids are the first choice for the treatment of mild pediatric psoriasis, while phototherapy and systemic therapy are used in children with moderate-severe psoriasis. According to the proposed treatment algorithm, biologics are the first line of systemic therapy., Conclusions: Targeted systemic therapies are changing the treatment of moderate-severe pediatric psoriasis, while topical corticosteroids continue to be the first choice for mild disease. Children-centered research is needed to further improve the treatment of pediatric psoriasis., (© 2022. The Author(s).)

Published
2022
Full Text
View/download PDF

49. Infantile Hemangioma and Cardiac Defects: a Puzzling Association. A Single-center Experience.

Author

Bassi A, Azzarelli A, Vaccaro A, and Mazzatenta C

Abstract

Objectives: to evaluate clinical chart of patients with IH who had cardiologic evaluation before propranolol therapy and to compare our findings with literature data., Introduction: Some studies have assessed the incidence of heart defects in children suffering from infantile hemangioma (IH) treated with propranolol, showing a possible higher prevalence of cardiac abnormalities in this group of patients., Methods: We retrospectively reviewed clinical charts of children with infantile hemangiomas referred to our dermatologic division from 2016 to 2021, who underwent our pediatric cardiology protocol screening before starting propranolol therapy., Results: A total of 60 infants were enrolled. Electrocardiograms were available for all the patients and echocardiography for 50/60 (83.3%) children. Electrocardiogram didn't reveal any alterations in most cases (pathologic in 2/60 ones, 3.3%) while echocardiograms revealed findings in 31/50 (51.7%) patients. Of these, persistent foramenovale, which was found in 14/50 patients (28%), was considered as non-pathologic. Interatrial septal defects were the main pathological finding in 15/50 patients (30%), as single defect or in association with other abnormalities., Conclusions: Our study confirms the presence of a higher rate of cardiologic findings in patients with infantile hemangioma evaluated before starting oral propranolol, compared to the known rate of those defects in healthy newborns. We also confirm that interatrial septal defects are the most frequent pathologic finding with a higher prevalence compared to published studies. Large prospective studies are needed to clarify a possible association of pathological cardiac findings in all patients with infantile hemangiomas and thereafter to evaluate the possible effect of propranolol therapy on these defects during time., Competing Interests: Competing interests: None., (©2022 Bassi et al.)

Published
2022
Full Text
View/download PDF

50. Cutis marmorata telangiectatica congenita being caused by postzygotic GNA11 mutations.

Author

Schuart C, Bassi A, Kapp F, Wieland I, Pagliazzi A, Losch H, Mazzatenta C, Bacci GM, Oranges T, Schanze D, Mohnike K, Nanda A, Fischer J, Zenker M, and Happle R

Subjects
Capillaries abnormalities, GTP-Binding Protein alpha Subunits, Humans, Livedo Reticularis, Mutation, Vascular Malformations, Glaucoma, Nevus complications, Skin Diseases, Vascular complications, Skin Diseases, Vascular diagnosis, Skin Diseases, Vascular genetics, Telangiectasis congenital, Telangiectasis genetics
Abstract

Cutis marmorata telangiectatica congenita (CMTC) is characterized by coarse-meshed capillary malformations arranged in asymmetrically distributed patches. The disorder may be associated with hyper- or hypoplastic limbs, syndactyly, cleft palate, and glaucoma. Because the disease usually occurs sporadically, the concept of a lethal mutation surviving by mosaicism was proposed about 30 years ago. Here we describe three children with CMTC due to a postzygotic GNA11 mutation c547C > T (p.Arg183Cys), documented in saliva (patient 1) or lesional cutaneous tissue (patients 2 and 3). All three individuals had widespread and asymmetric CMTC which was present from birth and became fainter during the first years of life. Variably associated anomalies included glaucoma, choroidal capillary malformation, and body asymmetry. In previous case reports, postzygotic GNA11 mutations were documented in two cases of phacomatosis cesiomarmorata, being characterized by CMTC coexisting with segmental dermal melanocytosis. Moreover, postzygotic GNA11 mutations were noted in two CMTC patients described under the incorrect diagnosis of "nevus vascularis mixtus". Hence, the present cases convincingly support the concept that CMTC can be caused by mosaic GNA11 mutations and thus belongs to the GNA11-Related Capillary Nevus (GNARCAN) spectrum. In two other bona fide cases of CMTC, however, we were unable to find a mutation in GNA11, which may be explained either by our inability to detect a very low percentage of mutant cells or by genetic heterogeneity of the phenotype., (Copyright © 2022. Published by Elsevier Masson SAS.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results